Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
CNY 21.55
(-0.23%)
CNY 21.55
(-0.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.56 Billion CNY | 16.57% |
| 2022 | 2.19 Billion CNY | 13.76% |
| 2021 | 1.93 Billion CNY | 20.39% |
| 2020 | 1.6 Billion CNY | 12.36% |
| 2019 | 1.42 Billion CNY | 35.01% |
| 2018 | 1.05 Billion CNY | 24.71% |
| 2017 | 848.31 Million CNY | 21.73% |
| 2016 | 696.89 Million CNY | 13.97% |
| 2015 | 611.48 Million CNY | 15.09% |
| 2014 | 531.3 Million CNY | 101.29% |
| 2013 | 263.95 Million CNY | 38.11% |
| 2012 | 191.11 Million CNY | 29.84% |
| 2011 | 147.18 Million CNY | 33.17% |
| 2010 | 110.52 Million CNY | -8.95% |
| 2009 | 121.38 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.7 Billion CNY | 0.72% |
| 2024 Q2 | 2.68 Billion CNY | 2.19% |
| 2024 Q1 | 2.62 Billion CNY | 2.42% |
| 2023 FY | 2.56 Billion CNY | 16.57% |
| 2023 Q3 | 2.51 Billion CNY | 2.87% |
| 2023 Q1 | 2.25 Billion CNY | 2.72% |
| 2023 Q4 | 2.56 Billion CNY | 2.05% |
| 2023 Q2 | 2.44 Billion CNY | 8.1% |
| 2022 Q1 | 1.97 Billion CNY | 2.09% |
| 2022 FY | 2.19 Billion CNY | 13.76% |
| 2022 Q4 | 2.19 Billion CNY | 2.39% |
| 2022 Q3 | 2.14 Billion CNY | 8.45% |
| 2022 Q2 | 1.97 Billion CNY | 0.36% |
| 2021 Q3 | 1.85 Billion CNY | 10.8% |
| 2021 Q4 | 1.93 Billion CNY | 4.23% |
| 2021 Q2 | 1.67 Billion CNY | -1.02% |
| 2021 Q1 | 1.69 Billion CNY | 5.32% |
| 2021 FY | 1.93 Billion CNY | 20.39% |
| 2020 Q2 | 1.42 Billion CNY | -1.83% |
| 2020 Q1 | 1.45 Billion CNY | 1.66% |
| 2020 FY | 1.6 Billion CNY | 12.36% |
| 2020 Q3 | 1.56 Billion CNY | 9.6% |
| 2020 Q4 | 1.6 Billion CNY | 2.73% |
| 2019 FY | 1.42 Billion CNY | 35.01% |
| 2019 Q4 | 1.42 Billion CNY | 3.93% |
| 2019 Q3 | 1.37 Billion CNY | 10.96% |
| 2019 Q2 | 1.23 Billion CNY | -0.79% |
| 2019 Q1 | 1.24 Billion CNY | 17.99% |
| 2018 Q3 | 1 Billion CNY | 12.44% |
| 2018 Q2 | 891.04 Million CNY | -1.35% |
| 2018 Q1 | 903.27 Million CNY | 6.48% |
| 2018 FY | 1.05 Billion CNY | 24.71% |
| 2018 Q4 | 1.05 Billion CNY | 5.59% |
| 2017 Q2 | 728.56 Million CNY | -0.04% |
| 2017 Q4 | 848.31 Million CNY | 5.26% |
| 2017 FY | 848.31 Million CNY | 21.73% |
| 2017 Q3 | 805.91 Million CNY | 10.62% |
| 2017 Q1 | 728.83 Million CNY | 4.58% |
| 2016 FY | 696.89 Million CNY | 13.97% |
| 2016 Q2 | 607.98 Million CNY | -4.94% |
| 2016 Q1 | 639.6 Million CNY | 4.6% |
| 2016 Q4 | 696.89 Million CNY | 5.1% |
| 2016 Q3 | 663.1 Million CNY | 9.07% |
| 2015 Q3 | 577.75 Million CNY | 8.04% |
| 2015 Q2 | 534.74 Million CNY | 5.82% |
| 2015 FY | 611.48 Million CNY | 15.09% |
| 2015 Q1 | 505.31 Million CNY | -4.89% |
| 2015 Q4 | 611.48 Million CNY | 5.84% |
| 2014 Q2 | 466.96 Million CNY | -1.87% |
| 2014 Q1 | 475.85 Million CNY | 80.28% |
| 2014 Q4 | 531.3 Million CNY | 4.52% |
| 2014 FY | 531.3 Million CNY | 101.29% |
| 2014 Q3 | 508.33 Million CNY | 8.86% |
| 2013 Q4 | 263.95 Million CNY | 5.17% |
| 2013 Q1 | - CNY | -100.0% |
| 2013 Q2 | 223.51 Million CNY | 0.0% |
| 2013 FY | 263.95 Million CNY | 38.11% |
| 2013 Q3 | 250.97 Million CNY | 12.28% |
| 2012 Q4 | 191.11 Million CNY | 0.0% |
| 2012 FY | 191.11 Million CNY | 29.84% |
| 2011 FY | 147.18 Million CNY | 33.17% |
| 2010 FY | 110.52 Million CNY | -8.95% |
| 2009 FY | 121.38 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 13.9 Billion CNY | 81.579% |
| Zhejiang Zhenyuan Share Co., Ltd. | 2.98 Billion CNY | 14.142% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.06 Billion CNY | -141.635% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 3.02 Billion CNY | 15.427% |
| Yifan Pharmaceutical Co., Ltd. | 11.49 Billion CNY | 77.719% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 847.56 Million CNY | -202.298% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 36.52 Billion CNY | 92.985% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 2.89 Billion CNY | 11.371% |
| Boai NKY Medical Holdings Ltd. | 4.01 Billion CNY | 36.26% |